Malignant lymphoma after diphenylhydantoin (dilantin) therapy

A history of prolonged diphenylhydantoin (Dilantin) therapy was reported by 8 of 516 patients (1.6%) with Hodgkin's disease or non‐Hodgkin's lymphoma, as compared with 3 of 516 patients (0.6%) with other cancers, and 2 of 516 (0.4%) tumor‐free individuals. The findings, together with other published data, suggest a small excess risk of malignant lymphomas in patients receiving long‐term treatment with this drug. The immunosuppressive effects of chronic diphenylhydantoin therapy may be involved in the pathogenesis of these neoplasms.

[1]  E. Trell,et al.  Malignant lymphogranulomatosis and anticonvulsant therapy. , 2009, Acta medica Scandinavica.

[2]  R. Lukes,et al.  Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease. , 1975, The New England journal of medicine.

[3]  R. Lukes,et al.  Immunologic characterization of human malignant lymphomas , 1974, Cancer.

[4]  J. Clemmesen,et al.  Are anticonvulsants oncogenic? , 1974, Lancet.

[5]  Tashima Ck,et al.  Letter: Lymphoma and anticonvulsive therapy. , 1974 .

[6]  C. Tashima,et al.  Lymphoma and Anticonvulsive Therapy , 1974 .

[7]  S. Shapiro,et al.  Diphenylhydantoin and selected congenital malformations. , 1973, The New England journal of medicine.

[8]  E. Creagan,et al.  Non-Hodgkin's lymphoma in childhood: epidemiologic features. , 1973, Journal of the National Cancer Institute.

[9]  R. Hoover,et al.  Risk of cancer in renal-transplant recipients. , 1973, Lancet.

[10]  T. Waldmann,et al.  Immunodeficiency disease and malignancy. Various immunologic deficiencies of man and the role of immune processes in the control of malignant disease. , 1972, Annals of internal medicine.

[11]  P. Grob,et al.  Immunological Abnormalities and Hydantoins , 1972, British medical journal.

[12]  D. Harris,et al.  Is phenytoin carcinogenic? , 1972, Lancet.

[13]  T. Sorrell,et al.  Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin). , 1971, Lancet.

[14]  R. W. Miller.  Transplacental chemical carcinogenesis in man. , 1971, Journal of the National Cancer Institute.

[15]  H. Kaplan.  Role of Immunologic Disturbance in Human Oncogenesis: Some Facts and Fancies , 1971, British Journal of Cancer.

[16]  W. Burnett,et al.  Vaginal cancer after maternal treatment with synthetic estrogens. , 1971, The New England journal of medicine.

[17]  R. Oates,et al.  PHENYTOIN AND THE PSEUDOLYMPHOMA SYNDROME , 1971, The Medical journal of Australia.

[18]  J. J. Anthony.  Malignant lymphoma associated with hydantoin drugs. , 1970, Archives of neurology.

[19]  P. R. Scaglione,et al.  Pseudolymphoma induced by diphenylhydantoin. , 1970, The Journal of pediatrics.

[20]  J. Fraumeni,et al.  Hodgkin's disease in childhood: an epidemiologic study. , 1969, Journal of the National Cancer Institute.

[21]  R. Gams,et al.  Hydantoin-induced pseudo-pseudolymphoma. , 1968, Annals of internal medicine.

[22]  S. Sommers,et al.  The development of Hodgkin's disease and lymphoma during anticonvulsant therapy. , 1966, Blood.

[23]  R. Schwartz,et al.  Malignant Lymphomas Following Allogenic Disease: Transition from an Immunological to a Neoplastic Disorder , 1965, Science.

[24]  A. Mauer,et al.  DIPHENYLHYDANOIN-INDUCED HYPERSENSITIVITY REACTION. , 1965, The Journal of pediatrics.

[25]  L. Ackerman,et al.  Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphomas , 1959, Cancer.